Gisadenafil besylate

Comparisons of the pharmacokinetics and tolerability of fixed-dose combinations of amlodipine besylate/losartan and amlodipine camsylate/losartan in healthy subjects: a randomized, open-label, single-dose, two-period, two-sequence crossover study.[Pubmed:27703330]

Drug Des Devel Ther. 2016 Sep 20;10:3021-3028.

BACKGROUND: A fixed-dose combination (FDC) of amlodipine and losartan has been used to reduce blood pressure in patients whose hypertension is not sufficiently controlled with either drug alone. The aim of this study was to evaluate the pharmacokinetic (PK) characteristics and tolerability of an FDC of 6.94 mg amlodipine besylate (5 mg as amlodipine)/50 mg losartan potassium compared to an FDC of 5 mg amlodipine camsylate/50 mg losartan potassium in healthy subjects. SUBJECTS AND METHODS: A randomized, open-label, single-dose, two-period, two-sequence crossover study was conducted on 46 healthy male subjects. Blood concentrations were measured by liquid chromatography-tandem mass spectrometry. Blood samples were collected up to 144 hours post dose for each period. PK parameters were calculated in each treatment group using a noncompartmental method. The 90% confidence intervals (CIs) of the geometric mean ratios of the two treatments for the maximum plasma concentration (Cmax) and the area under the concentration curve from time zero to the last quantifiable time point (AUC0-t) were estimated. Tolerability assessments were performed for all subjects who received the drug at least once. RESULTS: The PK profiles of the two treatments were similar. For amlodipine, the geometric mean ratios (90% CIs) of amlodipine besylate to amlodipine camsylate for the Cmax and AUC0-t were 0.98 (0.94-1.01) and 0.97 (0.93-1.01), respectively. The corresponding values for losartan were 0.91 (0.81-1.02) and 1.05 (0.98-1.12), respectively. The incidence of adverse events was not significantly different between the two treatments, and both were well tolerated. CONCLUSION: An FDC of 6.94 mg amlodipine besylate (5 mg as amlodipine)/50 mg losartan potassium produced similar results to an FDC of 5 mg amlodipine camsylate/50 mg losartan potassium treatment with respect to the PK parameters of amlodipine and losartan based on Cmax and AUC0-t values. The amlodipine besylate/losartan potassium combination was well tolerated by healthy male subjects.

Molecular insight into atypical instability behavior of fixed-dose combination containing amlodipine besylate and losartan potassium.[Pubmed:28064090]

J Pharm Biomed Anal. 2017 Mar 20;136:66-80.

Combination therapy with the use of fixed-dose combinations (FDCs) is evincing increasing interest of prescribers, manufacturers and even regulators, evidently due to the primary benefit of improved patient compliance. However, owing to potential of drug-drug interaction, FDCs require closer scrutiny with respect to their physical and chemical stability. Accordingly, the purpose of the present study was to explore stability behavior of a popular antihypertensive combination of amlodipine besylate (AML) and losartan potassium (LST). Physical mixtures of the two drugs and multiple marketed formulations were stored under accelerated conditions of temperature and humidity (40 degrees C/75% RH) in a stability chamber and samples were withdrawn after 1 and 3 months. The physical changes were observed visibly, while chemical changes were monitored by HPLC employing a method that could separate the two drugs and all other components present. The combination revealed strong physical instability and also chemical degradation of AML in the presence of LST. Interestingly, three isomeric interaction products of AML were formed in the combination, which otherwise were reported in the literature to be generated on exposure of AML free base above its melting point. The same unusual products were even formed when multiple marketed FDCs were stored under accelerated conditions outside their storage packs. However, these were absent when AML alone was stored in the same studied conditions. Therefore, reasons for physical and chemical incompatibility and the mechanism of degradation of AML in the presence of LST were duly explored at the molecular level. The outcomes of the study are expected to help in development of stable FDCs of the two drugs.

Phlebitis as a consequence of peripheral intravenous administration of cisatracurium besylate in critically ill patients.[Pubmed:27698008]

BMJ Case Rep. 2016 Oct 3;2016. pii: bcr-2016-216448.

This case report series describes 3 cases of cisatracurium besylate associated phlebitis after an infusion period of 14-20 hours. No similar cases have been reported in the literature. Association of phlebitis with another neuromuscular blocking agent, atracurium, has been described in the literature. The acidity of atracurium is thought to be the main cause. It is recommended that atracurium is administered only via central venous catheters when indicated to infuse over prolonged periods of time due to the acidity. Cisatracurium is a stereoisomer of atracurium and as such has the same molecular weight. Although cisatracurium also has a similar acidity as atracurium, a recommendation concerning infusion via a central venous catheter is lacking. We suggest prolonged administration of cisatracurium besylate only via centrally placed venous catheters or if not possible to careful monitor relevant peripheral intravenous sites to diminish the risks of phlebitis and associated complications or other cutaneous reactions.

Conductive Polymeric Ionic Liquid/Fe3O4 Nanocomposite as an Efficient Catalyst for the Voltammetric Determination of Amlodipine Besylate.[Pubmed:28118570]

J AOAC Int. 2017 Mar 1;100(2):406-413.

A novel conductive polymeric ionic liquid (IL)-Fe3O4 nanocomposite (represented as PIL-Fe3O4) based on inorganic-organic hybrid material was synthesized using two different methods. Nuclear magnetic resonance, Fourier transform infrared, X-ray diffraction, and field emission scanning electron microscopy characterized the structures of IL, Fe3O4 nanoparticles, and PIL-Fe3O4. The electrochemical sensors based on PIL-Fe3O4-modified glassy carbon electrode were fabricated, and each of these nanocomposites was examined for the ability to determine amlodipine besylate (AMD). The electrochemical study of the modified electrodes, as well as its efficiency for the electro-oxidation of AMD, was described in 0.1 M phosphate-buffered solution (pH 7.0) using voltammetric methods. The results exhibit a linear dynamic range from 1 to 500 nM and a detection limit of 0.36 nM. Finally, the modified electrode was used for the determination of AMD in pharmaceutical and biological samples.

Gisadenafil besylate (UK 369003-26) is a specific, orally active phosphodiesterase 5 (PDE5) inhibitor with an IC50 of 3.6 nM and prevents degradation of cyclic guanosine monophosphate (cGMP).

Gisadenafil besylate,334827-98-4,Natural Products,Phosphodiesterases, buy Gisadenafil besylate , Gisadenafil besylate supplier , purchase Gisadenafil besylate , Gisadenafil besylate cost , Gisadenafil besylate manufacturer , order Gisadenafil besylate , high purity Gisadenafil besylate